DOCSLIB.ORG

Bivalirudin Infusion to Reduce Ventricular Infarction: the Open

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Bivalirudin Infusion to Reduce Ventricular Infarction: the Open CLINICAL RESEARCH CORONARY INTERVENTIONS Euro 1 Intervention 2 3 4 publish-ahead-of-print May 2017 2017;13-online 5 6 7 8 9 10 11 Bivalirudin infusion to reduce ventricular infarction: the open- 12 13 label, randomised Bivalirudin Infusion for Ventricular 14 15 InfArction Limitation (BIVAL) study 16 17 18 Robert Jan van Geuns1*, MD, PhD; Georgios Sideris2, MD, PhD; Niels Van Royen3, MD, PhD; 19 Rami El Mahmoud4, MD; Roberto Diletti1, MD, PhD; Claire Bal dit Sollier2, PhD; 20 Jerome Garot5, MD, PhD; Nina Van Der Hoeven3, MD, PhD; Bernardo Cortese6, MD; 21 Li Ding7, PhD; Ilknur Lechthaler8; Efthymios N. Deliargyris9, MD; Prodromos Anthopoulos8, MD; 22 Ludovic Drouet2, MD, PhD 23 24 1. Erasmus MC, Rotterdam, the Netherlands; 2. Hôpital AP-HP Lariboisière, Paris, France; 3. Vrije Universiteit Amsterdam, 25 Amsterdam, the Netherlands; 4. Hôpital Ambroise Paré, Boulogne, France; 5. Hôpital Privé Jacques Cartier, Ramsay Générale 26 de Santé, ICPS, Massy, France; 6. A.O. Fatebenefratelli, Milan, Italy; 7. The Medicines Company, Parsippany, NJ, USA; 27 8. The Medicines Company, Zurich, Switzerland; 9. Science and Strategy Consulting Group, Basking Ridge, NJ, USA 28 29 30 KEYWORDS Abstract 31 Aims: The aim of the study was to investigate whether bivalirudin versus unfractionated heparin (UFH) 32 • adjunctive reduces infarct size (IS) for primary percutaneous coronary intervention (PPCI) in large acute myocardial 33 pharmacology infarction (AMI). 34 • clinical trials 35 Methods and results: • magnetic This multicentre open-label trial randomised 78 patients undergoing PPCI for large 36 resonance imaging AMI to bivalirudin or UFH. The primary endpoint was IS, assessed by cardiac magnetic resonance (CMR) 37 (MRI) five days after PPCI. Secondary endpoints included index of microcirculatory resistance (IMR), CMR- 38 • other imaging assessed microvascular obstruction (MVO) and ejection fraction, and biomarkers for thrombin activity and 39 modalities cell injury. No difference was observed in mean IS at five days (25.0±19.7 g for bivalirudin vs. 27.1±20.7 g 40 • ST-elevation for UFH; p=0.75). Early MVO was numerically lower with bivalirudin (5.3±5.8 g vs. 7.7±6.3 g; p=0.17), 41 myocardial with no significant difference in ejection fraction at 90 days (54.6±12.0% vs. 49.1±12.1%; p=0.11). In 42 infarction (STEMI) the biomarkers, thrombin-antithrombin complexes were reduced by 4.8 ug/L over the first day for bivali- 43 rudin versus an increase of 1.9 ug/L in the heparin arm (p=0.0003). Acute IMR was lower (43.5±21.6 vs. 44 68.7±35.8 mmHg×s, respectively; p=0.014). In a planned interim analysis, an approximate 11% reduction DOI: 45 in IS was observed with bivalirudin; the trial was discontinued for futility. 46 10.4244/EIJ-D-17-00307 47 Conclusions: This study did not achieve its primary endpoint of significant infarct size reduction in 48 PPCI by prolonged bivalirudin infusion compared to UFH, even though complete thrombin inhibition was 49 achieved in the acute phase, with a lower myocardial microcirculation resistance at the end of the procedure. 50 51 52 *Corresponding author: Thoraxcenter, Room Ba585, Erasmus Medical Center, ‘s-Gravendijkwal 230, 3015 CE Rotterdam, 53 the Netherlands. E-mail: [email protected] © Europa Digital & Publishing 2017. All rights reserved. SUBMITTED ON 07/04/2017- REVISION RECEIVED ON 1st 25/04/2017 / 2 nd 03/05/2017 - ACCEPTED ON 04/05/2017 1 Euro Intervention 54 Abbreviations reduces reperfusion injury and improves myocardial healing, 55 AMI acute myocardial infarction resulting in a smaller final IS. For this we used cardiac magnetic 3 56 APPROACH Alberta Provincial Project for Outcome Assessment resonance (CMR) imaging, the gold standard for measuring IS , 2017;13-online publish-ahead-of-print May 2017 2017;13-online 57 in Coronary Heart Disease which can also provide a reliable quantitative measurement of 58 BARC Bleeding Academic Research Consortium global left ventricular parameters and identify prolonged MVO. In 59 BIVAL Bivalirudin Infusion for Ventricular InfArction a subgroup, we measured invasively the index of microcirculatory 60 Limitation resistance (IMR) at the end of the procedure, which predicts clini- 61 CMR cardiac magnetic resonance cal outcomes4. Finally, we assessed the direct and indirect effects 62 DTPA diethylenetriamine penta-acetic acid of bivalirudin and UFH on coagulation, platelets, and leucocytes 63 EDV end-diastolic volume to explore the effect of thrombin inhibition on IS. 64 IMR index of microcirculatory resistance 65 IQR interquartile range Methods 66 IS infarct size BIVAL was a multicentre, open-label, prospective, randomised con- 67 ITT intention-to-treat trolled trial conducted at four sites in the Netherlands and France 68 LVEF left ventricular ejection fraction in patients undergoing PPCI for a large myocardial infarction. 69 MPO myeloperoxidase Adults with STEMI who presented >20 minutes and <12 hours 70 MSI myocardial salvage index after symptom onset were eligible if they fulfilled the follow- 71 MVO microvascular obstruction ing angiographic criteria: Thrombolysis In Myocardial Infarction 72 PPCI primary percutaneous coronary intervention (TIMI) 0 or 1 flow in the infarct-related artery (IRA); angiographic 73 SD standard deviation score ≥21 (sizeable infarction, based on initial angiogram) accord- 74 STEMI ST-segment elevation myocardial infarction ing to the APPROACH score5; and eligible for PPCI. Patients with 75 TAT thrombin−antithrombin complexes a history of Q-wave myocardial infarction or who had received 76 TIMI Thrombolysis In Myocardial Infarction antithrombotic therapy other than UFH at first medical contact 77 UFH unfractionated heparin were excluded. Use of glycoprotein IIb/IIIa inhibitors was permit- 78 ted only as bail-out therapy for the treatment of no-reflow pheno- 79 Introduction menon or giant thrombus, defined as >2 times the diameter of the 80 Primary percutaneous coronary intervention (PPCI) for vessel. The full study criteria are detailed online (https://clinical- 81 ST-elevation myocardial infarction (STEMI) reduces infarct size trials.gov: NCT02565147). 82 (IS) and improves survival. Even with rapid restoration of epicar- All patients provided written informed consent. The sponsor 83 dial flow, final IS is considerable, with a significant contribution (The Medicines Company, Parsippany, NJ, USA) was responsi- 84 from reperfusion injury and microvascular obstruction (MVO) due ble for funding, protocol development in collaboration with the 85 to oedema and capillary obstruction by microthrombi. Final IS executive committee and the clinical coordinating centre, on-site 86 depends on several factors including the occlusion location, dura- monitoring and safety surveillance, statistical analyses, and data 87 tion of occlusion, the burst of thrombin triggered by plaque rup- management. The institutional review board at each site approved 88 ture and coronary intervention involving thrombus manipulation1. the study protocol and activities. 89 Beyond its role in coagulation, thrombin is proinflamma- 90 tory and is implicated in reperfusion injury. On a cellular level, STUDY MEDICATIONS 91 thrombin activates platelets, endothelial cells and leucocytes; con- All patients received, as soon as logistically possible, aspirin at an 92 sequently, it exerts a potent proinflammatory action, with a throm- initial dose of 150-325 mg orally (or 250-500 mg intravenously) 93 bogenic and deleterious effect on the microcirculation especially and a loading dose of a P2Y12 inhibitor. Administration of UFH at 94 downstream from the culprit lesion2. The formation of monocyte- first medical contact or before the angiogram was allowed as per 95 platelet aggregates increases within minutes after PCI, reaching usual practice. 96 a peak within 2-4 hours2. Thrombin is formed and released from Randomisation (1:1) was carried out using an interactive voice/ 97 the occluding thrombus and by the intra-arterial manipulations of web response system. All patients randomised to the bivalirudin arm 98 vessel reopening during and after completion of PPCI2. Bivalirudin received a bolus of 0.75 mg/kg and an infusion of 1.75 mg/kg/hr for 99 directly inhibits both clot-bound and unbound thrombin, whereas the duration of the procedure and for four hours after completion of 100 heparin is less effective against clot-bound thrombin2. Thrombin PPCI to maintain consistent thrombin inhibition, as (during STEMI) 101 inhibition by a prolonged 4-hour bivalirudin infusion after PPCI thrombin exerts activity beyond the restoration of flow in the IRA. 102 may therefore reduce inflammation and reperfusion injury. Patients randomised to UFH were administered a dose as per stand- 103 The primary objective of the Bivalirudin Infusion for ard institutional practice. In cases where activated clotting time was 104 Ventricular InfArction Limitation (BIVAL) study was to investi- used to inform UFH dosing, a target value of ≥250 seconds was rec- 105 gate whether treatment with bivalirudin infusion for four hours ommended. Randomisation was stratified by duration of symptom 106 versus unfractionated heparin (UFH) for PPCI in large STEMI onset to randomisation (<6 hrs versus ≥6 hrs) and site. 2 The BIVAL study Euro Intervention 107 PRIMARY AND SECONDARY OUTCOMES were measured: TAT and change in TAT (which expresses the 108 The primary outcome was the difference in IS in the bivalirudin net effect of thrombin generation and its inhibition), myeloper- 109 versus UFH arm, assessed by CMR performed five days (defined oxidase, and microparticles. Care was maximum to respect the 110 as 5 days±72 hours from randomisation) after PPCI. Key second- preanalytical requirements strictly. Within two hours of blood publish-ahead-of-print May 2017 2017;13-online 111 ary outcomes were the difference between bivalirudin and UFH collection, platelet-free plasma aliquots were prepared by double 112 in other CMR-derived variables of myocardial recovery five days centrifugation. Plasma aliquots were frozen to –80°C and shipped 113 after PPCI, namely LVEF and MVO. LVEF and IS were also to the core laboratory (<3 months) for measurement of biomark- 114 assessed by CMR at 90 days.
Load more

Recommended publications
  • Kengrexal, INN-Cangrelor Tetrasodium
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Kengrexal 50 mg powder for concentrate for solution for injection/infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains cangrelor tetrasodium corresponding to 50 mg cangrelor. After reconstitution 1 mL of concentrate contains 10 mg cangrelor. After dilution 1 mL of solution contains 200 micrograms cangrelor. Excipient with known effect Each vial contains 52.2 mg sorbitol. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for concentrate for solution for injection/infusion. White to off-white lyophilised powder. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Kengrexal, co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable. 4.2 Posology and method of administration Kengrexal should be administered by a physician experienced in either acute coronary care or in coronary intervention procedures and is intended for specialised use in an acute and hospital setting. Posology The recommended dose of Kengrexal for patients undergoing PCI is a 30 micrograms/kg intravenous bolus followed immediately by 4 micrograms/kg/min intravenous infusion. The bolus and infusion should be initiated prior to the procedure and continued for at least two hours or for the duration of the procedure, whichever is longer. At the discretion of the physician, the infusion may be continued for a total duration of four hours, see section 5.1.
    [Show full text]
  • Heparin Induced Thrombocytopenia – Adult – Inpatient– Clinical Practice Guideline
    Heparin Induced Thrombocytopenia – Adult – Inpatient– Clinical Practice Guideline Table of Contents EXECUTIVE SUMMARY ........................................................................................................... 2 SCOPE ...................................................................................................................................... 6 METHODOLOGY ...................................................................................................................... 6 DEFINITIONS (OPTIONAL): ..................................................................................................... 7 INTRODUCTION ....................................................................................................................... 7 RECOMMENDATIONS .............................................................................................................. 7 BENEFITS/HARMS OF IMPLEMENTATION ...........................................................................17 IMPLEMENTATION PLAN AND TOOLS ........................ERROR! BOOKMARK NOT DEFINED. REFERENCES .........................................................................................................................17 APPENDIX A ............................................................................................................................17 Note: Active Table of Contents Click to follow link CPG Contact for Changes: CPG Contact for Content: Name: Philip J Trapskin, PharmD,BCPS Name: Anne E. Rose, PharmD Phone Number: 263-1328 Phone Number:
    [Show full text]
  • Anticoagulation Dosing Guideline for Adult COVID-19 Patients
    Anticoagulation Dosing Guideline for Adult COVID-19 Patients Enoxaparin is the preferred first line anticoagulant for patients diagnosed with COVID-19. The incidence of HIT with enoxaparin is less than 1%. VTE Prophylaxis: VTE prophylaxis will be considered for COVID-19 patients who are low risk. Low risk COVID-19 patient 1. Not receiving mechanical ventilation 2. D-Dimer < 6 mg/L 3. ESRD on iHD without clotting Kidney Function BMI (kg/m2) Dosing of Enoxaparin Concern for HIT or LMWH Failure CrCL ≥ 30 mL/min 18.5-39.9 30mg SUBQ Q12H Consult Hematology 40-49.9 40mg SUBQ Q12H ≥ 50 60mg SUBQ Q12H CrCL < 30 mL/min 18.5-39.9 30mg SUBQ Q24H Consult Hematology OR ≥ 40 40mg SUBQ Q24H ESRD/AKI on RRT Special Population: < 18.5 (or weight < 50kg) Heparin 2500 SUBQ Q8H Consult Hematology *Contraindications: Platelets < 25 K/uL or Fibrinogen < 50 mg/dL or active bleeding Therapeutic anticoagulation Therapeutic anticoagulation will be considered for COVID-19 patients who are considered high risk or diagnosed with an acute VTE. High risk COVID-19 patient (for all hospitalized patients): Receiving mechanical ventilation AND D-dimer > 6 mg/L OR Acute kidney injury (Scr increase 0.3 mg/dL above baseline) +/- CVVHD/AVVHD/SLED or IHD with clotting Anti-Xa level goals for enoxaparin therapy (when indicated): 1. Therapeutic peak LMWH level (Drawn 4 hours after 3rd dose): 0.6-1 anti-Xa units/mL 2. Therapeutic trough LMWH level (Drawn 1 hour prior to 3rd dose): < 0.5 anti-Xa units/mL Kidney Function BMI Dosing of Enoxaparin Concern for HIT or (kg/m2) LMWH
    [Show full text]
  • Transition of Anticoagulants 2019
    Transition of Anticoagulants 2019 Van Hellerslia, PharmD, BCPS, CACP, Brand Generic Clinical Assistant Professor of Pharmacy Practice, Angiomax bivalirudin Temple University School of Pharmacy, Philadelphia, PA Arixtra fondaparinux Bevyxxa betrixaban Pallav Mehta, MD, Assistant Professor of Medicine, Coumadin warfarin Division of Hematology/Oncology, Eliquis apixaban MD Anderson Cancer Center at Cooper, Camden, NJ Fragmin dalteparin Lovenox enoxaparin Reviewer: Kelly Rudd, PharmD, BCPS, CACP, Pradaxa dabigatran Clinical Specialist, Anticoagulation, Bassett Medical Center, Savaysa edoxaban Cooperstown, NY Xarelto rivaroxaban From To Action Apixaban Argatroban/ Wait 12 hours after last dose of apixaban to initiate parenteral anticoagulant. In cases of Bivalirudin/ high bleeding risk, consider omitting initial bolus when transitioning to heparin infusion. Enoxaparin/ Dalteparin/ Fondaparinux/ Heparin Apixaban Warfarin When going from apixaban to warfarin, consider the use of parenteral anticoagulation as a bridge (eg, start heparin infusion or therapeutic enoxaparin AND warfarin 12 hours after last dose of apixaban and discontinue parenteral anticoagulant when INR is therapeutic). Apixaban affects INR so that initial INR measurements during the transition may not be useful for determining the appropriate dose of warfarin. Apixaban Betrixaban, Wait 12 hours from last dose of apixaban to initiate betrixaban, dabigatran, edoxaban, or Dabigatran, rivaroxaban. Edoxaban, or Rivaroxaban Argatroban Apixaban, Start apixaban, betrixaban, dabigatran,
    [Show full text]
  • Legemiddelforbruket I Norge 2012–2016 Drug Consumption in Norway 2012–2016
    2017:1 LEGEMIDDELSTATISTIKK EVT STIKKTITTEL INN HER Legemiddelforbruket i Norge 2012–2016 Drug Consumption in Norway 2012–2016 ISSN 1890-9647 Legemiddelforbruket i Norge 2012–2016 Drug Consumption in Norway 2012–2016 Solveig Sakshaug Hanne Strøm Christian Berg Hege Salvesen Blix Irene Litleskare Tove Granum Utgitt av Folkehelseinstituttet / Published by Norwegian Institute of Public Health Området for Psykisk og fysisk helse Avdeling for Legemiddelepidemiologi Mars 2017 Tittel/Title: Legemiddelstatistikk 2017:1 Legemiddelforbruket i Norge 2012-2016/Drug Consumption in Norway 2012-2016 Forfattere/Authors: Solveig Sakshaug (redaktør) Hanne Strøm Christian Berg Hege Salvesen Blix Irene Litleskare Tove Granum Bestilling/Order: Rapporten kan lastes ned som pdf på Folkehelseinstituttets nettsider: www.fhi.no/ The report is available as pdf format only and can be downloaded from the www.fhi.no Layout omslag: www.fetetyper.no Kontaktinformasjon/Contact information Folkehelseinstituttet/Norwegian Institute of Public Health P.O.Box 4404 Nydalen N-0403 Oslo Tel: +47 21 07 70 00 ISSN: 1890-9647 ISBN 978-82-8082-826-2 elektronisk utgave Sitering/Citation: Sakshaug, S (red), Legemiddelforbruket i Norge 2012-2016 [Drug Consumption in Norway 2012-2016], Legemiddelstatistikk 2017:1, Oslo: Folkehelseinstituttet, 2017. Tidligere utgaver/Previous editions: 1977: Legemiddelforbruket i Norge 1974 - 1976 1978: Legemiddelforbruket i Norge 1975 - 1977 1980: Legemiddelforbruket i Norge 1975 - 1979 1981: Legemiddelforbruket i Norge 1980 1982: Legemiddelforbruket
    [Show full text]
  • Antithrombotic Agents in the Management of Sepsis
    Antithrombotic Agents in the Management of Sepsis !"#$ Loyola University Medical Center, Maywood, Illinois-60153, USA ABSTRACT Sepsis, a systemic inflammatory syndrome, is a response to infection and when associated with mul- tiple organ dysfunction is termed, severe sepsis. It remains a leading cause of mortality in the critically ill. The response to the invading bacteria may be considered as a balance between proinflammatory and antiinflammatory reaction. While an inadequate proinflammatory reaction and a strong antiinflammatory response could lead to overwhelming infection and death of the patient, a strong and uncontrolled pro- inflammatory response, manifested by the release of proinflammatory mediators may lead to microvas- cular thrombosis and multiple organ failure. Endotoxin triggers sepsis by releasing various mediators inc- luding tumor necrosis factor-alpha and interleukin-1(IL-1). These cytokines activate the complement and coagulation systems, release adhesion molecules, prostaglandins, leukotrienes, reactive oxygen speci- es and nitric oxide (NO). Other mediators involved in the sepsis syndrome include IL-1, IL-6 and IL-8; arachidonic acid metabolites; platelet activating factor (PAF); histamine; bradykinin; angiotensin; comp- lement components and vasoactive intestinal peptide. These proinflammatory responses are counterac- ted by IL-10. Most of the trials targeting the different mediators of proinflammatory response have failed due a lack of correct definition of sepsis. Understanding the exact pathophysiology of the disease will enable better treatment options. Targeting the coagulation system with various anticoagulant agents inc- luding antithrombin, activated protein C (APC), tissue factor pathway inhibitor (TFPI) is a rational appro- ach. Many clinical trials have been conducted to evaluate these agents in severe sepsis.
    [Show full text]
  • Legemiddelforbruket I Norge 2014–2018 Drug Consumption in Norway 2014–2018
    LEGEMIDDELSTATISTIKK 2019:1 Legemiddelforbruket i Norge 2014–2018 Drug Consumption in Norway 2014–2018 Legemiddelforbruket i Norge 2014–2018 Drug Consumption in Norway 2014–2018 Solveig Sakshaug Kristine Olsen Christian Berg Hege Salvesen Blix Live Storehagen Dansie Irene Litleskare Tove Granum Utgitt av Folkehelseinstituttet/Published by Norwegian Institute of Public Health Område for Helsedata og digitalisering Avdeling for Legemiddelstatistikk Mai 2019 Tittel/Title: Legemiddelstatistikk 2019:1 Legemiddelforbruket i Norge 2014–2018/Drug Consumption in Norway 2014–2018 Forfattere/Authors: Solveig Sakshaug (redaktør) Kristine Olsen Christian Berg Hege Salvesen Blix Live Storehagen Dansie Irene Litleskare Tove Granum Bestilling: Rapporten kan lastes ned som pdf på Folkehelseinstituttets nettsider: www.fhi.no The report is only available as pdf from www.fhi.no Grafisk design omslag: Fete Typer Kontaktinformasjon/Contact information: Folkehelseinstituttet/Norwegian Institute of Public Health P.O.Box 222 Skøyen N-0213 Oslo Tel: +47 21 07 70 00 ISSN:1890-9647 ISBN elektronisk utgave: 978-82-8406-011-8 Sitering/Citation: Sakshaug, S (red), Legemiddelforbruket i Norge 2014–2018 [Drug Consumption in Norway 2014–2018], Legemiddelstatistikk 2019:1, Oslo: Folkehelseinstituttet, 2019. Tidligere utgaver/Previous editions: 1977: Legemiddelforbruket i Norge 1974–1976 1978: Legemiddelforbruket i Norge 1975–1977 1980: Legemiddelforbruket i Norge 1975–1979 1981: Legemiddelforbruket i Norge 1980 1982: Legemiddelforbruket i Norge 1977–1981 1984: Legemiddelforbruket
    [Show full text]
  • Angiox, INN-Bivalirudin
    authorised ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS longer no product Medicinal 1 1. NAME OF THE MEDICINAL PRODUCT Angiox 250 mg powder for concentrate for solution for injection or infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 250 mg bivalirudin. After reconstitution 1 ml contains 50 mg bivalirudin. After dilution 1 ml contains 5 mg bivalirudin. For the full list of excipients see section 6.1. 3. PHARMACEUTICAL FORM Powder for concentrate for solution for injection or infusion (powder for concentrate). White to off-white lyophilised powder. authorised 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Angiox is indicated as an anticoagulant in adult patients undergoing percutaneous coronary intervention (PCI), including patients with ST-segment elevationlonger myocardial infarction (STEMI) undergoing primary PCI. Angiox is also indicated for the treatment of adult patientsno with unstable angina/non-ST segment elevation myocardial infarction (UA/NSTEMI) planned for urgent or early intervention. Angiox should be administered with acetylsalicylic acid and clopidogrel. 4.2 Posology and method of administration Angiox should be administeredproduct by a physician experienced in either acute coronary care or in coronary intervention procedures. Posology Patients undergoing PCI, including patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI The recommended dose of bivalirudin for patients undergoing PCI is an intravenous bolus of 0.75Medicinal mg/kg body weight followed immediately by an intravenous infusion at a rate of 1.75 mg/kg body weight/hour for at least the duration of the procedure. The infusion of 1.75 mg/kg body weight/hour may be continued for up to 4 hours post-PCI and at a reduced dose of 0.25 mg/kg body weight/hour for an additional 4 – 12 hours as clinically necessary.
    [Show full text]
  • Cleveland Clinic Anticoagulation Management Program (C-Camp)
    CLEVELAND CLINIC ANTICOAGULATION MANAGEMENT PROGRAM (C-CAMP) 1 Table of Contents I. EXECUTIVE SUMMARY ......................................................................................................................................... 6 II. VENOUS THROMBOEMBOLISM RISK ASSESSMENT AND PROPHYLAXIS ............................................. 9 III. RECOMMENDED PROPHYLAXIS OPTIONS FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM. ........................................................................................................................................ 10 IIIA. RECOMMENDED PROPHYLAXIS OPTIONS FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM BASED ON RISK FACTOR ASSESSMENT ............................................................. 12 A) UNFRACTIONATED HEPARIN (UFH) ................................................................................................................... 14 B) LOW MOLECULAR WEIGHT HEPARIN (LMWH) ENOXAPARIN (LOVENOX®) .............................................. 14 C) FONDAPARINUX/ (ARIXTRA®) …………………………………………………………………………..……16 D) RIVAROXABAN (XARELTO®) .......................................................................................................................... 16 E) DESIRUDIN (IPRIVASK®)………………………………………………………………………………..…….17 F) WARFARIN/COUMADIN®) ............................................................................................................................... 16 G) ASPIRIN……………………………………………………………………………………………………..……18 H) INTERMITTENT PNEUMATIC COMPRESSION DEVICES .....................................................................................
    [Show full text]
  • Transition of Anticoagulants 2016
    Transition of Anticoagulants 2016 Van Hellerslia, PharmD, BCPS, CACP, Clinical Assistant Professor of Pharmacy Practice, Brand Generic Temple University School of Pharmacy, Philadelphia, PA Angiomax bivalirudin Arixtra fondaparinux Pallav Mehta, MD, Assistant Professor of Medicine, Coumadin warfarin Division of Hematology/Oncology, Eliquis apixaban MD Anderson Cancer Center at Cooper Fragmin dalteparin Lovenox enoxaparin Reviewer: Kelly Rudd, PharmD, BCPS, CACP, Clinical Specialist, Anticoagulation, Pradaxa dabigatran Savaysa edoxaban Bassett Medical Center, Cooperstown, New York Xarelto rivaroxaban From To Action Apixaban Argatroban/ Wait 12 hours after last dose of apixaban to initiate parenteral anticoagulant. In cases of Bivalirudin/ high bleeding risk, consider omitting initial bolus when transitioning to heparin infusion. Enoxaparin/ Dalteparin/ Fondaparinux/ Heparin Apixaban Warfarin When going from apixaban to warfarin, consider the use of parenteral anticoagulation as a bridge (eg, start heparin infusion/enoxaparin and warfarin 12 hours after last dose of apixaban and discontinue parenteral anticoagulant when INR is therapeutic ≥2). Apixaban Dabigatran, Wait 12 hours from last dose of apixaban to initiate dabigatran, edoxaban, or rivaroxaban. Edoxaban, or Rivaroxaban Argatroban Apixaban, Start apixaban, dabigatran, edoxaban, or rivaroxaban within 2 hours of stopping argatroban. Dabigatran, Edoxaban, or Rivaroxaban Argatroban Enoxaparin/ If no hepatic insufficiency, start parenteral anticoagulant within 2 hours of stopping Dalteparin/ argatroban. If there is hepatic insufficiency, start parenteral anticoagulant after 2-4 hours of Fondaparinux/ stopping argatroban. Heparin *The use of enoxaparin/dalteparin/heparin assumes the patient does not have heparin allergy or heparin-induced thrombocytopenia. Argatroban Warfarin Argatroban must be continued when warfarin is initiated and co-administration should continue for at least 5 days. Argatroban elevates the INR.
    [Show full text]
  • The Printed Journal Includes an Image Merely for Illustration
    Comment 6 Fox KA, Poole-Wilson P, Clayton TC, et al. 5-year outcome of an interventional 11 Rao SV, O’Grady K, Pieper KS, et al. Impact of bleeding severity on clinical strategy in non-ST-elevation acute coronary syndrome: the British Heart outcomes among patients with acute coronary syndromes. Am J Cardiol Foundation RITA 3 randomised trial. Lancet 2005; 366: 914–20. 2005; 96: 1200–06. 7 Lagerqvist B, Husted S, Kontny F, and The Fast Revascularisation during 12 Stone GW, McLaurin BT, Cox DA, for the ACUITY Investigators. InStability in Coronary artery disease (FRISC-II) Investigators. 5-year Bivalirudin for patients with acute coronary syndromes. N Engl J Med outcomes in the FRISC-II randomised trial of an invasive versus a 2006; 355: 2203–16. non-invasive strategy in non-ST elevation acute coronary syndrome: 13 The OASIS-6 Trial Group. Eff ects of fondaparinux on mortality and a follow-up study. Lancet 2006; 368: 998–1004. reinfarction in patients with acute ST-segment elevation myocardial 8 Stone GW, Moses JW, Ellis SG, et al. Safety and effi cacy of sirolimus- and infarction: the OASIS-6 randomized trial. JAMA 2006; 295: 1519–30. paclitaxel-eluting coronary stents. N Engl J Med 2007; 356: 998–1008. 14 Rosamond W, Flegal K, Friday G, for the American Heart Association 9 Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact Statistics Committee and Stroke Statistics Subcommittee. Heart disease of bleeding on prognosis in patients with acute coronary syndromes. and stroke statistics—2007 update: a report from the American Heart Circulation 2006; 114: 774–82.
    [Show full text]
  • Guidelines for Using Bivalirudin During Cardiopulmonary Bypass Surgery
    Guidelines for Using Bivalirudin During Cardiopulmonary Bypass Surgery During cardiopulmonary bypass procedures, systemic anticoagulation to prevent thrombosis in the patient as well as the circuit is utilized. Heparin is the most common agent used, but in selective circumstances, alternate form of anticoagulation may be considered. In patients with heparin induced thrombocytopenia (HIT), heparin resistance, or significant thrombosis while on therapeutic heparin, alternative anticoagulation management using a direct thrombin inhibitor (DTI) may be desired. Patients with organ failure will have elimination rates substantially longer than observed in healthier individuals. Bivalirudin has the shortest elimination half-life among all DTI’s with lower dependence on renal or liver function for removal (~80% enzymatic) which is a benefit in patients who have a high risk of bleeding, organ failure, or who may require an invasive procedure. Bivalirudin can also be removed by hemofiltration. Of note, bivalirudin is primarily metabolized by thrombin and blood proteases, which results in loss of effect and potential coagulation when blood is stagnant, such as at the cardiopulmonary bypass (CPB) circuit filter, in the surgical field, or at the cannulas tips when off CPB. Thus, gelling of pooled blood in the surgical may occur with bivalirudin and may not reflect insufficient levels of anticoagulation. The dosing presented below is a guide to aid in the initiation of bivalirudin infusion during CPB surgery; however alterations may occur based on the clinical presentation of the patient (e.g. patient’s renal function, bleeding and clotting risks, ability to transfuse). The Anticoagulation Service can be contacted for assistance with dosing in CPB.
    [Show full text]